Everything below concerns peptidase cleavage. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-01. Numbers and descriptions here follow the published literature rather than marketing material.
The mechanisms attributed to semax are inferred from animal and cell studies rather than traced to one confirmed target. The most frequently cited pathway involves increased expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal and cortical tissue. Some work points to engagement of melanocortin receptors, particularly MC4, which the parent ACTH fragment can activate. Effects on dopaminergic and serotonergic signalling have also been reported. No single account explains all observed results, and the relative weight of each pathway remains unsettled.
Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.
Circulation time for the peptide is short because peptidases cleave it readily. The Pro-Gly-Pro tail is thought to slow breakdown compared with the bare ACTH fragment, but the gain appears modest. Absorption after intranasal dosing is limited, and only a fraction of a dose is expected to reach the central nervous system. Laboratory concentrations therefore sit well above levels achieved systemically, a gap that complicates translation from bench findings to clinical claims.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid from research suppliers |
| Solubility | Freely soluble in water | Also dissolves in aqueous buffers; solutions are used fresh |
| Typical storage temperature | -20 °C for lyophilized powder | Short-term transport at 2-8 °C is common |
| Common analytical method | Reverse-phase HPLC | Paired with mass spectrometry for identity confirmation |
| Common synonyms | ACTH(4-10) analogue; MEHFPGP | N-terminal methionine retained in the chain |
Routine characterization relies on reversed-phase high-performance liquid chromatography to establish purity and on mass spectrometry to confirm molecular identity. Electrospray ionization and matrix-assisted laser desorption ionization are both used for mass verification. Amino acid analysis and peptide mapping can detect sequence errors. Common impurities include truncated sequences, methionine sulfoxide formed by oxidation, and deamidated products. Chromatograms are usually recorded near 214 nm, where the peptide backbone absorbs, and purity is reported as the percentage area of the principal peak.
Verification of a supplied batch generally combines a certificate of analysis with independent testing, because certificates are self-reported documents. A typical package includes a chromatographic trace, a mass spectrum, and a stated water or counter-ion content. Batch-to-batch consistency matters more than a single purity figure when results are compared across experiments. No single mandatory standard governs research-grade peptide release, so laboratories are expected to define their own acceptance criteria. Residual trifluoroacetate from purification is a frequently overlooked counter-ion.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.
Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.
=== United Kingdom === The legal status of powdered alcohol in United Kingdom is uncertain, although parliament saw no dangers from the sale of powdered alcohol, aside from the loss of tax revenue. In a January 2015 answer to a parliamentary question, Lord Bates wrote "The Government is aware of powdered alcohol from media reports and the banning of the product in five states of the United States of America. The Government is aware of powdered alcohol being marketed and made available in the coming years to buy in England and Wales."
Diabetes burden and access to care vary widely between and within countries. Between 1990 and 2022, diabetes prevalence rose faster in low and middle income countries than in high-income countries. In 2022, more than half of adults aged 30 and over with diabetes were not taking medication for it, and treatment coverage was lowest in low and middle income countries. A pooled analysis of 1,108 population-based studies estimated that in most countries, especially low and middle income ones, treatment had not increased enough to keep pace with rising prevalence, and that the gap in treatment coverage between the countries widened from 56 percentage points in women and 43 in men in 1990 to 78 and 71 respectively in 2022. WHO reported in 2021 that essential diabetes medicines were available in only about half of facilities in low and lower middle income countries, compared to about 80% of facilities globally. The International Diabetes Federation estimated that 252 million adults aged 20–79 were unaware they had diabetes in 2024. Risk also differs between ethnic groups. South Asian people tend to develop type 2 diabetes earlier in life and often at a normal body mass index. In a study of British Pakistani and British Bangladeshi participants, those with a high genetic risk of both insulin deficiency and unfavourable fat distribution were diagnosed about 8 years earlier, at a BMI about 3 kg/m² lower, than those at low genetic risk. Disparities are also documented for Indigenous peoples.
=== Processed products === More and more, potatoes are consumed and cooked through industrially processed products, mainly frozen products, most often precooked, or dehydrated (e.g., potato flakes, granules, flour). The share of processed products exceeds that of table potatoes in some Western countries (United States, Canada, Northern Europe). In Germany, for example, in 2003–2004, processed potatoes accounted for 34.3 kg per capita per year, compared to 32.5 kg for table potatoes. In the United States, the use of fresh potatoes represented, in 2007, only one third of the total consumption. Most of the time, these are "ready to cook" products, which have the advantage of facilitating the preparation of meals, eliminating the need for tedious peeling, and which can be stored more easily and longer than fresh tubers. The most commonly used are dehydrated flaked mashed potatoes, or instant mashed potatoes, and pre-cooked frozen French fries. The latter are more commonly consumed in the catering industry. The simplest are peeled and pre-cooked vacuum-packed potatoes, which belong to the category of fresh products, known as fifth range. Canned potatoes (tins or jars) are also available on the market, sometimes mixed with carrots or peas. Potato chips are a special case, since this product is consumed directly, without any culinary preparation, and most often outside the meal.
Sources: en.wikipedia.org
=== Water === The biological half-life of water in a human is about 7 to 14 days. It can be altered by behavior. Drinking large amounts of alcohol will reduce the biological half-life of water in the body. This has been used to decontaminate patients who are internally contaminated with tritiated water. The basis of this decontamination method is to increase the rate at which the water in the body is replaced with new water.
All mRNA templates used for mRNA display technology have puromycin at their 3' end. As translation proceeds, the ribosome moves along the mRNA template, and once it reaches the 3' end of the template, the fused puromycin will enter ribosome's A site and be incorporated into the nascent peptide. The mRNA-peptide fusion is then released from the ribosome (Figure 1). To synthesize an mRNA-peptide fusion, the fused puromycin is not the only modification to the mRNA template. Oligonucleotides and other spacers need to be incorporated along with the puromycin to provide flexibility and proper length for the puromycin to enter the A site. Ideally, the linker between the 3' end of an mRNA and the puromycin has to be flexible and long enough to allow the puromycin to enter the A site upon translation of the last codon. This enables the efficient production of high-quality, full-length mRNA-peptide fusions. Rihe Liu et al. optimized the 3'-puromycin oligonucleotide spacer. They reported that dA25 (a nucleotide sequence of 25 deoxyadenosine residues) in combination with a Spacer 9 (Glen Research), and dAdCdCP at the 5' terminus worked the best for the fusion reaction. They found that linkers longer than 40 nucleotides and shorter than 16 nucleotides showed greatly reduced efficiency of fusion formation. Also, when the sequence rUrUP was present adjacent to the puromycin, fusion did not form efficiently.
Injectable filler is a substance made to be injected into connective tissues, such as skin, cartilage or even bone, for cosmetic or medical purposes. The most common application of injectable fillers is to change one's facial appearance, but they also are used to reduce symptoms of osteoarthritis, treat tendon or ligament injuries, support bone and gum regeneration, and for other medical applications. Injectable fillers can be in the form of hydrogel or gels made from pulverized grafts. Injectable fillers have risen in popularity mostly due to the wide application of dermal fillers in 1980s. Their premise is to help fill in facial wrinkles, provide facial volume, and augment facial features. Potential side effects include bruising, allergic reactions which may cause scarring or lumps, or infections from improper sterilisation. This may include HIV infection. Blindness due to retrograde (opposite the direction of normal blood flow) embolization into the ophthalmic and retinal arteries can occur.
=== Brand names === It is marketed under the brand name Rivotril by Roche in Argentina, Australia, Austria, Bangladesh, Belgium, Brazil, Canada, Colombia, Costa Rica, Croatia, the Czech Republic, Denmark, Estonia, Germany, Hungary, Iceland, Ireland, Italy, China, Mexico, the Netherlands, Norway, Portugal, Peru, Pakistan, Romania, Serbia, South Africa, South Korea, Saudi Arabia, Spain, Turkey, and the United States; Emcloz, Linotril, Lonazep, Clotrin and Clonotril in India and other parts of Europe; under the name Riklona in Indonesia and Malaysia; and under the brand name Klonopin by Roche in the United States. Other names, such as Antelepsin, Clonoten, Ravotril, Rivotril, Iktorivil, Clonex (Israel), Paxam, Petril, Naze, Zilepam and Kriadex, are used throughout the world. In August 2021, Roche Australia transferred Rivotril to Pharmaco Australia Ltd.
Sources: en.wikipedia.org
It consists mainly of animal experiments and small clinical reports, with much of the clinical material published in Russian-language journals. Large independent trials are scarce. Separating reliable effects from chance findings is consequently difficult.
A fraction of an intranasal dose is thought to reach the central nervous system, and this route is favoured partly for that reason. The proportion is not well characterized. Direct measurement in humans remains difficult with current methods.
Raised BDNF and NGF expression has been reported across several animal studies, which makes the signal fairly consistent. Whether the same change occurs in humans at usable doses is not established. It is best treated as a working hypothesis rather than a confirmed clinical mechanism.
It is registered as a pharmaceutical product in Russia, where it is typically supplied as a nasal solution. In most other countries it is not an approved drug and is traded as a research chemical instead. Approval status depends entirely on the jurisdiction involved.